moa of tirzepatide What is the mechanism action (MOA) of (dual GIP and GLP-1 receptor agonist)? What is the mechanism of

Tirzepatide the approved label starts at 2.5 mg once weekly and escalates in 2.5 mg steps at intervals of at least four weeks, to a maintenance dose of up to 15 mg once weekly

Retatrutide primarily operates on a systemic, hormonal level, influencing appetite, satiety, and glucose regulation through its triple agonism of GIP, GLP-1, and glucagon receptors

R., Little, A

Warning Possible side effects may include nausea, vomiting, diarrhea, constipation, stomach pain, headache, tiredness, indigestion, bloating, reduced appetite, or injection-site reactions

If this drug is made accessible in New Zealand as a weight-loss medication and is funded by Pharmac for that use as well, this could have considerably positive health outcomes for the country, taking pressure off the hospital system by reducing things like heart attacks and strokes. Why is this important